FDA approves onabotulinumtoxinA to prevent chronic migraine
FDA has approved onabotulinumtoxinA (Botox, Allergan Inc.) injection to prevent headaches in adult patients with chronic migraine.
FDA has approved onabotulinumtoxinA (Botox, Allergan Inc.) injection to prevent headaches in adult patients with chronic migraine. OnabotulinumtoxinA is injected about every 12 weeks at multiple sites around the head and neck to try to dull future headache symptoms.
Irvine, Calif.-based Allergan provided FDA substantial evidence of safety and effectiveness to support the new indication of prophylaxis of headaches in patients with chronic migraine, an agency spokesperson told Formulary.
Botox has not been shown to work for the treatment of migraine headaches that occur 14 days or less per month or for other forms of headache.
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More
